SCNTP™ · the programme and the people behind it

About the SCNTP™ Programme

The short answer. SCNTP™ — the Somatic Cell Nuclear Transfer Protocol — is Panacea Bio Chem's research programme on one specific problem: patient-matched pluripotent stem cells exist in the published literature, but their cost keeps them out of ordinary reach. The programme works on the protocol, chemistry, and preservation side of that cost problem. It is a direction of work, presented as such.

What the programme is working on

The science of resetting a body cell to pluripotency is established: human embryonic stem-cell lines were derived by somatic cell nuclear transfer in 2013[PubMed], and induced pluripotent stem cells reach the same reset with four defined factors and no egg — the discovery that took the 2012 Nobel Prize.[PubMed] What is not established is a way to do it at a cost routine medicine could carry: oocytes are scarce, micromanipulation is artisanal, and cloning efficiencies stay in single digits even in the best primate work.[PubMed]

SCNTP™ exists to close that gap — a protocol designed from the start for cost, paired with the company's peptide, formulation, and preservation technology. The full scientific case, with every source, is the homepage essay; the record the programme builds on is the legacy page.

Somatic cell nuclear transfer in one viewA four-step schematic: a donor body cell contributes its nucleus; an egg cell's own nucleus is removed; the nucleus is transferred and the egg activated; the resulting cells grow into a patient-matched pluripotent stem-cell line.1 · Donor body cellits nucleus carries thepatient's whole genome2 · Enucleated eggthe egg's own nucleusis removed3 · Transfer + activationthe egg's cytoplasm resetsthe donor nucleus4 · Pluripotent linepatient-matched stem cellsgrown in culture
Somatic cell nuclear transfer, schematic. Scientific illustration — not experimental imagery.

Who leads the programme

Bogdan Dicoias, biochemist and inventor, originated the SCNTP™ programme and leads it: Director of Panacea Bio Chem Ltd and Scientific Director at Biogenther, his Dominican Republic company, through which he is directly involved in this field — biogenther.com.

SCNTP™ is a proprietary Panacea Bio Chem programme developed and invented by Bogdan Dicoias. Its parameters are not publicly disclosed.

The organizations behind it

Panacea Bio Chem Ltd — the programme's home and publisher: a research company built around formulation, preservation, and process engineering for delicate biologicals, including the Lyoprester® dual-chamber system. The hub of the research network is panaceabiochem.co.uk.

Biogenther — Bogdan Dicoias's Dominican Republic company, and his direct involvement in the regenerative-medicine field: biogenther.com.

Follow the work, or reach it

Follow the programme's network: Instagram (Lyoprester) · Facebook (Panacea Bio Chem) · X (Panacea Bio Chem).

Contact: contact@panaceabiochem.com — or use the contact page.

Field status: no SCNT-derived cell therapy has regulatory approval anywhere as of September 2026 — the homepage documents the evidence. Concept and programme direction: Bogdan Dicoias, biochemist and inventor. Published by Panacea Bio Chem Scientific Communications. Sources on this page link PubMed directly; identifiers re-verified 11 September 2026. Nothing here is medical advice.